Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of CTX310

Next Previous
Trial Profile

Clinical study of CTX310

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX-310 (Primary)
  • Indications Cardiovascular disorders; Dyslipidaemias; Hyperlipoproteinaemia type II; Hypertriglyceridaemia
  • Focus Adverse reactions; First in man

Most Recent Events

  • 06 May 2025 According to a CRISPR Therapeutics media release, Top-line data reported are from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2[0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant as of a data cutoff date of April 16, 2025.
  • 06 May 2025 According to a CRISPR Therapeutics media release, The Company plans to present the CTX310 Phase 1 data at a medical meeting in the second half of 2025.
  • 06 May 2025 Results(n=10) presented in the CRISPR Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top